Boehringer Ingelheim confirmed this month that the last participant in its Phase 3 SYNCHRONIZE-1 obesity trial completed the 76-week primary endpoint visit, the April 26 peptide news digest reported ↗. Topline data are expected in the first half of 2026. Survodutide ↗ is a once-weekly injectable peptide that activates two receptors at once: GLP-1, the receptor that semaglutide ↗ and tirzepatide ↗ already hit, and the glucagon receptor. The drug is co-developed with Zealand Pharma.
If approved, survodutide would be the third major GLP-1-class obesity drug, behind semaglutide (Wegovy ↗, Ozempic ↗) and tirzepatide (Mounjaro ↗, Zepbound ↗). The dual-agonism design is the bet. Semaglutide acts on GLP-1 alone. Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide), a related gut hormone that improves the metabolic profile and has been credited with tirzepatide's larger weight loss compared to semaglutide. Survodutide replaces the GIP arm with glucagon, which directly stimulates the body's resting energy expenditure rather than modulating the insulin response. The wager is that the glucagon signal adds calories burned to the calories not consumed.
The 76-week primary endpoint visit completion matters because it is the gating event for topline. Phase 3 obesity trials typically read out three to six months after the last patient finishes the protocol, depending on data cleaning, statistical analysis plan finalization, and adjudication of cardiovascular events. Boehringer's H1 2026 timeline aligns with that window. The company has also confirmed that SYNCHRONIZE-CVOT, the cardiovascular outcomes arm of the program, is fully enrolled. The two readouts together would, if positive, give regulators what they want to see for a label that competes with the incumbents on safety as well as efficacy.
The mechanistic question is whether the additional glucagon arm translates into better weight loss without the side-effect profile that earlier glucagon-containing peptides showed. Glucagon raises blood sugar by signaling the liver to release glucose from glycogen stores, which is the response the hormone evolved to drive. In patients with diabetes or pre-diabetes, that signal cuts the wrong way. Designing a peptide that hits the glucagon receptor for thermogenic benefit without aggravating glycemic control is the engineering problem the SYNCHRONIZE program was meant to answer in humans. The Phase 3 readout is what answers it.
Survodutide also lands in a calendar already crowded with obesity-drug events. Lilly reports Q1 earnings April 30 and Novo Nordisk follows May 6 ↗. Foundayo (orforglipron) ↗, Lilly's non-peptide oral GLP-1, is in early launch. Novo's oral semaglutide just hit its pediatric endpoint ↗. Survodutide enters this market not as a first-mover but as a third entrant betting on a different mechanistic axis.
Zealand Pharma's role in the program is the other thing the readout will affect. Zealand discovered the original peptide and licensed it to Boehringer. The company also has its own pipeline of GLP-1/glucagon and GLP-1/amylin combinations, several of which are being co-developed with larger players. A positive SYNCHRONIZE-1 readout would validate the dual-agonism design beyond Lilly's tirzepatide and reset the licensing economics for similar molecules in earlier development.
The H1 2026 window is wide. Whether topline lands in May, June, or later in the half determines whether survodutide becomes part of the obesity-drug news cycle through ADA 2026 in early summer, or slips to the autumn scientific-meeting season. Either way, the 76-week visit completion was the only event in survodutide's Phase 3 timeline that could have moved. It happened on schedule.